Human Follicle Stimulating Hormone (Gonal F)

A major gonadotropin secreted by the human adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and the LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. The alpha subunit is common in the three human pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity.

Also Known As:

Networked: 117 relevant articles (6 outcomes, 16 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Howles, C M: 3 articles (02/2009 - 03/2000)
2.	Balasch, J: 3 articles (03/2005 - 11/2000)
3.	Bias, Peter: 2 articles (01/2015 - 01/2015)
4.	Lammerich, Andreas: 2 articles (01/2015 - 01/2015)
5.	Loumaye, Ernest: 2 articles (07/2014 - 02/2002)
6.	O'Dea, Louis: 2 articles (09/2009 - 10/2008)
7.	Warne, David W: 2 articles (08/2009 - 02/2002)
8.	Chang, R Jeffrey: 2 articles (09/2006 - 12/2003)
9.	Malcom, Pamela J: 2 articles (09/2006 - 12/2003)
10.	Garolla, Andrea: 2 articles (09/2005 - 02/2002)

Related Diseases

1.	Infertility (Sterility) 09/01/2006 - "We performed a randomized double-blind placebo-controlled study on seminal parameters and endocrine profile of 30 normogonadotropic patients with male factor infertility to assess the efficacy of treatment with recombinant human FSH (rhFSH) at high doses (300 IU on alternate days) for a period of >or=4 months. " 11/01/2009 - "The aim of the study was to prospectively investigate the efficacy of recombinant human follicle-stimulating hormone (rhFSH) in the treatment of various types of male-factor infertility at a single university hospital. " 01/01/2014 - "The efficacy of recombinant human follicle-stimulating hormone (rhFSH) in the treatment of normogonadotropic patients with male-factor infertility was assessed. " 11/01/2009 - "The efficacy of recombinant human follicle-stimulating hormone in the treatment of various types of male-factor infertility at a single university hospital." 09/01/2005 - "Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study."
2.	Hypogonadism (Hypergonadotropic Hypogonadism) 10/01/2010 - "Efficacy of recombinant human follicle stimulating hormone at low doses in inducing spermatogenesis and fertility in hypogonadotropic hypogonadism." 04/01/2013 - "An observational clinical and molecular study was designed to evaluate the effects of the administration of recombinant human FSH on sperm DNA fragmentation in men with a non-classical form of hypogonadotropic hypogonadism and idiopathic oligoasthenoteratozoospermia. " 06/01/2010 - "The 2:1 combination of r-hFSH and r-hLH has been seen as an optimum preparation in terms of safety and clinical efficacy in hypogonatrophic hypogonadism patients. " 10/01/2008 - "Among patients with hypogonadotrophic hypogonadism (HH) treated with r-hFSH alone, a transition from LH dependence to independence was observed between basal LH values of > or = 1.2 IU/L and < or = 1.6 IU/L. " 02/01/2002 - "Efficacy and safety of recombinant human follicle-stimulating hormone in men with isolated hypogonadotropic hypogonadism."
3.	Anovulation 12/01/2001 - "The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain." 01/01/1998 - "European Puregon Collaborative Anovulation Study Group." 01/01/2015 - "XM17 is a recombinant human follicle-stimulating hormone (rhFSH) intended mainly for use in controlled ovarian hyperstimulation and the treatment of anovulation. " 04/01/1994 - "The past 12 months have seen the first reports of the clinical applications of recombinant human follicle-stimulating hormone (FSH), and there is an intriguing suggestion that long-acting opiate agonists may have a part to play in the management of anovulation of hypothalamic origin." 03/01/2005 - "Women with infertility due to anovulation and over-responding to FSH treatment were randomized to receive, in addition to 37.5 IU recombinant human FSH (rFSH), either placebo or different doses of rLH (6.8, 13.6, 30 or 60 microg) daily for a maximum of 7 days. "
4.	Ovarian Hyperstimulation Syndrome 01/01/2004 - "In recent years a number of publications have shown that chronic low-dose protocols are effective in reducing complications, in particular ovarian hyperstimulation syndrome (OHSS), especially if recombinant human follicle stimulating hormone (rhFSH) is used. " 05/01/2015 - "No difference in severe ovarian hyperstimulation syndrome was observed between treatment groups (Bemfola: 0.8%; Gonal-f: 0.8%). " 10/01/2006 - "Secondary outcomes included average initial and total recombinant hFSH dosage, serum E2 level on day of ovulation, number of oocytes retrieved, fertilization, number of top-quality embryos, endometrial thickness, implantation rate, pregnancy rate (PR), and incidence of ovarian hyperstimulation syndrome (OHSS). " 07/01/2003 - "Patients were randomly allocated on day 7 of stimulation to one of the two hCG administration criteria: [1] the E(2)-to-follicle > or =11 mm ratio was between 250 and 500 pmol/L/follicle and at least 2 follicles reached a mean diameter of 18 mm or [2] at least 2 follicles reached a mean diameter of 18 mm and the endometrium thickness was > or =8 mm. Duration and cumulative dose of recombinant human FSH, total number of growing follicles, oocytes retrieved, number and quality of embryos, pregnancy rates, and ovarian hyperstimulation syndrome (OHSS) rates. " 03/01/2000 - "There were seven cases (5.0%) of ovarian hyperstimulation syndrome in the r-hFSH group and three (2.2%), in the u-hFSH HP group (not significant). "
5.	Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal) 11/01/2000 - "Recombinant human follicle-stimulating hormone for ovulation induction in polycystic ovary syndrome: a prospective, randomized trial of two starting doses in a chronic low-dose step-up protocol." 11/01/2012 - "To assess the differences in follicular development comparing two sequential low-dose step-up and step-down protocols (A: 37.5 IU/day, B: 75 IU/day) with a step-down protocol (C: 150 IU/day) using recombinant human follicle stimulating hormone (rFSH) in women with polycystic ovarian syndrome (PCOS). " 01/01/1994 - "First established pregnancy and birth after induction of ovulation with recombinant human follicle-stimulating hormone in polycystic ovary syndrome." 10/17/1992 - "Pregnancy after induction of ovulation with recombinant human FSH in polycystic ovary syndrome." 04/01/2001 - "The present study compared ovarian performance and hormone concentrations, after ovulation induction, in polycystic ovarian syndrome (PCOS) patients, using recombinant human FSH (rhFSH) in low-dose step-up and modified step-down regimens. "

Related Drugs and Biologics

1.	Gonadotropins
2.	Human Follicle Stimulating Hormone (Gonal F)
3.	Luteinizing Hormone (Lutropin)
4.	Estradiol (Estrace)
5.	Testosterone (Sustanon)
6.	Hormones
7.	Prolactin
8.	Dehydroepiandrosterone (DHEA)
9.	Leptin
10.	inhibin B

Related Therapies and Procedures

1.	Hypophysectomy
2.	Individualized Medicine
3.	Injections
4.	Immunotherapy